Arca
Skip to content
Tools
Tools

Neuromyelitis optica

Drug research and approvals for neuromyelitis optica: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 47 studies of neuromyelitis optica are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 4 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 47
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 4
  • EU medicines: 2

Recruiting now

Newest posted first, of 47 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 5

Phase 2 12 of 14

Phase 1 or earlier 9

How its trials ended

133 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 22 whose ending is known, 45% met their primary endpoint, 5% missed it and 50% stopped early.

  • Ongoing5844%
  • Completed, result not reported3224%
  • Status unknown2116%
  • Met its primary endpoint108%
  • Stopped: other or unclear75%
  • Stopped: enrollment or feasibility43%
  • Missed its primary endpoint11%

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Dec 7, 2022A phase I, multicenter, open-label, uncontrolled study to evaluate pharmacokinetics, pharmacodynamics, safety, and tolerability of satralizumab in adult…EnspryngRocheClosed
May 16, 2022A phase 2/3, open-label, historical-controlled, single-arm, multicenter smdy to evaluate the efficacy, pharmacokinetics, pharmacodynamics, and safety of…ALXN1210AstraZeneca PharmaceuticalsOngoing
May 9, 2022An open-label multicenter study to evaluate the pharmacokinetics, pharmacodynamics, and safety of inebilizumab in pediatric subjects with neuromyelitis optica…Inebilizumab (VIB0551)AmgenPending
Nov 5, 2021Sakurabonsai: clinical, imaging and biomarker open-label study in neuromyelitis optica spectrum disorder (NMOSD) with satralizumab as an interventionSatralizumab (RO5333787) (SA237)RocheOngoing
Nov 3, 2020A multicenter, single arm, open-label study to evaluate the long-term safety and efficacy of satralizumab in patients with neuromyelitis optica spectrum…EnspryngRocheOngoing
Nov 13, 2019A phase 2/3 open-label, single-arm trial to evaluate the safety and activity of eculizumab in pediatric patients with relapsing neuromyelitis optica spectrum…SolirisAstraZeneca PharmaceuticalsOngoing
Oct 29, 2019A phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of ravulizumab in adult patients with neuromyelitis…ALXN1210AstraZeneca PharmaceuticalsOngoing
Apr 11, 2014A multicenter, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety, of SA237 as monotherapy in patients with…SA237RocheOngoing
Mar 20, 2014A double-masked, placebo-controlled study with open label period to evaluate the efficacy and safety of MEDI-551 in adult subjects with neuromyelitis optica…MEDI-551MedImmune LLCClosed
Jun 27, 2013A phase III, open-label, extension trial of ECU-NMO-301 to evaluate the safety and efficacy of eculizumab in patients with relapsing neuromyelitis (NMO)SolirisAstraZeneca PharmaceuticalsPending

FDA orphan designations

Approved first, then open designations, newest first
Mar 22, 2024UltomirisTreatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positiveAlexion Pharmaceuticals, Inc.Approved
Aug 14, 2020EnspryngTreatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positiveGenentech, Inc.Approved
Jun 11, 2020UpliznaUplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4…Horizon Therapeutics Ireland DACApproved
Jun 27, 2019SolirisSoliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4)…Alexion Pharmaceuticals, Inc.Approved
Feb 2, 2026RituximabTreatment of neuromyelitis optica spectrum disorderOddifact SASDesignated
Apr 24, 2023EdralbrutinibTreatment of neuromyelitis optica spectrum disordereVenus Pharmaceutical Lab Inc.Designated
Aug 25, 2016UblituximabTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorderTG Therapeutics, Inc.Designated
Mar 19, 2015CladribineTreatment of neuromyelitis optica and neuromyelitis optica spectrum disorderChord Therapeutics S.a.r.l.Designated

Medicines authorised in the EU

Newest first
Apr 25, 2022UpliznaInebilizumabAmgen Europe B.V.EMA ↗
Jun 24, 2021EnspryngSatralizumab · orphanRoche Registration GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.